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Background: Exercise-based spectral T-wave alternans (TWA) has been proposed as a noninvasive tool-identifying
patients at risk of sudden cardiac death (SCD) and cardiac mortality. Prior studies have indicated that ambulatory
electrocardiogram (AECG)-based TWA is an important alternative platform to exercise for risk stratification of cardiac
events. This study sought to review data regarding 24-hour AECG-based TWA and to discuss its potential role in risk
stratification of fatal cardiac events across a series of patient risk profiles.
Methods: Prospective clinical studies of the predictive value of AECG-based TWA obtained with daily activity published
between January 1990 and November 2014 were retrieved. Major endpoints included composite endpoint of SCD,
cardiac mortality, and severe arrhythmic events.
Results: Data were accumulated from 5 studies involving a total of 1,588 patients, including 317 positive and 1,271
negative TWA results. Compared with the negative group, positive group showed increased rates of SCD (hazard ratio
[HR]: 7.49, 95% confidence interval [CI]: 2.65 to 21.15), cardiac mortality (HR: 4.75, 95% CI: 0.42 to 53.55), and composite
endpoint (SCD, cardiac mortality, and severe arrhythmic events, HR: 5.94, 95% CI: 1.80 to 19.63). For the 4 studies
evaluating TWA measured using the modified moving average method, the HR associated with a positive versus
negative TWA result was 9.51 (95% CI: 4.99 to 18.11) for the composite endpoint.
Conclusions: The positive group of AECG-based TWA has a nearly six-fold risk of severe outcomes compared with
the negative group. Therefore, AECG-based TWA provides an accurate means of predicting fatal cardiac events.
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The T-wave alternans (TWA) phenomenon, a repeating
ABABAB pattern in the morphology and amplitude of
the ST-segment or T-wave, has long been recognized and
linked to arrhythmogenesis [1-3]. TWA has been pro-
posed as noninvasive means of stratifying patients for the
risk of sudden cardiac death (SCD) and cardiac mortality
[1,4,5].
TWA value can be obtained during exercise testing
(bicycle or treadmill) or AECG recording [1,2,5]. Exercise-* Correspondence: ctzhang@tjh.tjmu.edu.cn
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unless otherwise stated.based TWA has been mainly analyzed by frequency-
domain spectral method [1,2,4,6]. A target heart rate
range of 105 to 110 beats/min for a sustained period (>2
min) was determined for microvolt TWA assessed during
exercise testing [1,6]. Therefore, not all patients can
undergo a spectral TWA test, for example, patients taking
medications such as beta-blockers, digoxin, and those with
physical limitations. Recent study by Jackson et al. showed
that spectral method was not widely applicable in patients
hospitalized with acute decompensated heart failure, 49%
were ineligible for spectral TWA testing, due either to
physical inability to undertake the test, AF, or pacemaker
dependency [7]. In another study by Tapanainen et al.,
of the 379 consecutive post-acute myocardial infarctionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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during exercise test in only 53% of the cases [8].
Because of inability to achieve the target heart rate,
the presence of excessive ectopy, nonsustained TWA, or
excessive signal noise due to motion or respiration, there
is a relatively high incidence (19% to 46% of all cases) of
indeterminate test results [1,7,9-11]. For the prognostic
value of indeterminate TWA results, the results was
controversial. Some studies have suggested that an inde-
terminate TWA tests due to patient factors was a strong
predictor of SCD or cardiac arrest [8,10,12], but conflicting
opinions exists [7,9,13,14].
Ambulatory electrocardiogram (AECG) recording-based
TWA represents an important alternative platform to
stratify patients at risk for serious cardiac events [1,2].
TWA testing based on 24-hour Holter ECG recorded
during daily activity does not require heart rate elevation
and so overcomes some of the limitations of spectral
method [5,15-17]. Prior studies with AECG-based TWA
analysis have shown that an abnormal TWA result is
modestly associated with cardiac events and that a normal
result has a high negative predictive value [18-21]. How-
ever, negative studies have also appeared, including two
prospective studies in patients with chronic heart failure
[22] and AMI [23].
We therefore performed this systematic review and
meta-analysis to determine the utility of 24-hour Holter
AECG-based TWA for risk stratification of cardiac
events in a wide variety of patient populations.
Methods
Ethics statement
The Ethics Committee (IRB) of Tongji Hospital (Wuhan
City, Hubei Province, China) recognizes that this systematic
review and meta-analysis of de-identified, publicly available
data does not constitute “human subjects research” as
defined by relevant national regulations, and therefore
does not require Ethics Committee review.
Search criteria
A systematic review of the available literature was per-
formed according to the PRISMA (preferred reporting
items for systematic reviews and meta-analyses) guidelines
(Additional file 1). This article evaluates the potential
value of 24-hour Holter AECG recording-based TWA in
risk stratification of fatal cardiac events in a wide variety
of patient populations. We performed a systematic litera-
ture search for prospective studies published in English
between January 1990 and November 2014. The search
was restricted to full-text English publications and human
subjects. Using the terms "T wave alternans", "ambulatory
electrocardiogram (ECG)", "Holter", we searched the follow-
ing databases: MEDLINE, EMBASE, Cochrane Library,
International Network of Agencies for Health TechnologyAssessment, and the Web of Science. A second search
of articles published by authors identified in the initial
search and a review of the bibliographies of all articles
were performed to identify additional articles for review.
We also hand-searched reviews and previous meta-analysis
for additional potentially relevant studies.
We excluded review articles, abstracts, book chapters,
conference proceedings, and correspondence. If more than
one study reported on the same cohort, then we only used
the most recent publication of that cohort. Articles of sub-
cohorts were excluded if an article using the entire cohort
was previously included. When the same research study
was found in multiple journals or repositories, only one
instance of the study was included.Inclusion criteria
Studies were included if they met the following criteria:
1) prospective clinical study of ≥ 100 human subjects; 2)
24-hour Holter AECG-based TWA obtained with daily
activity; 3) reported meaningful clinical endpoints including
SCD, cardiac mortality, and/or ventricular arrhythmias; 4)
provided clear definition of positive or negative TWA.
Duplicate publications and studies with a follow-up of
less than 6 months were excluded.
Two investigators (Q.X. and Z.H.) independently re-
viewed the titles and abstracts of these articles and
excluded those that clearly did not meet the inclusion
criteria. A consensus was reached on which articles should
be completely reviewed for potential inclusion in this study.Data extraction
Two investigators (Q.X. and Z.H.) independently reviewed
potential articles blinded to the author, journal, and insti-
tution. Data for each article were abstracted, including
study design, inclusion and exclusion criteria, clinical
characteristics of participants, details regarding TWA
result, end points of the study, duration of follow-up,
raw data when provided, and reported findings, including
hazard ratios (HR).Quality analysis of study
We assessed study quality based on the following assess-
ment of the articles [9]: 1) the follow-up completed was
beyond 90% of the cohort, 2) adjudication of outcomes
was blinded to the results of TWA testing, and 3) a
multivariate analysis using other standard predictors of
cardiac events was performed. A study was considered
at least of fair quality if it fulfilled the first criteria. A
study was considered good quality if one of the other
two criteria was met. This quality assessment was not
used to assess study inclusion or exclusion, but was
included as a study characteristic.
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The outcomes of each study were presented as HR with
confidence interval (CI) of TWA for the prediction of
SCD, cardiac mortality, or severe arrhythmic events at
follow-up. After demonstration with Cochran’s Q test
and I2 statistic of the homogeneity of the results, we used
a random effects model developed by DerSimonian and
Laird [24]. Publication bias was evaluated with the use of
Begg’s test. Finally, we performed sensitivity analyses to
examine the influence of each study on the pooled esti-
mate by omitting each study one at a time. All statistical
tests were 2-sided and were evaluated at a significance
level of 0.05. STATA version 12.0 (College Station, TX,
USA) was used to conduct all analyses.
Results
Study characteristics
An initial literature search using the previously mentioned
search terms identified 963 potential articles for inclusion
in this study. After reviewing and eliminating clearly ineli-
gible studies, we identified 5 prospective studies involving
a total of 1,588 participants (Figure 1) [18-22]. One other
study did not provide enough primary data [23], anFigure 1 PRISMA flow diagram. Summary of the evidence search and seattempt was made to contact the author, but failed to
receive the original data. Therefore, this study was not
included in our current analysis. All studies were iden-
tified in MEDLINE, although some were also found in
other databases. All studies were classified as being of
good quality.Predictive accuracy of AECG-based TWA
The baseline characteristics of included studies, stratified
by the study of origin, are presented in Table 1. The
studies enrolled an overall number of 1,588 patients who
were followed up for an average of 33 months. Overall,
mean age was 64 years, 74% of patients were men, and
approximately 72% of patients had underlying ischemic
heart disease. A positive TWA result observed overall in
317 (20%) of the patients (Table 2), 87 (28%) patients
reached the endpoint. Whereas a negative result observed
in 1,271 (80%) of the patients (Table 2), 120 (9%) patients
reached the endpoint.
In the study by Monasterio et al. (Table 3) [22], for the
end point of cardiac mortality, the prognostic value of
TWA was negative (HR: 1.44, 95% CI: 0.97–2.13). Forlection.
Table 1 Characteristics of prospective cohort studies of AECG-based TWA
Study Total (n) Mean age (yrs) Men (%) ICD implanted (%) Population Mean LVEF (%) Average follow-up
(months)
Sakaki et al. 2009 [19] 295 66 72 7 LVEF < 40%, dilated
left ventricle
34 13
Sulimov et al. 2012 [20] 111 64 76 - Post-MI 46.6 12
Yu et al. 2012 [21] 219 56 81 0 Acute MI >35%* 16
Monasterio et al.
2012 [22]
650 63 71 - symptomatic CHF
corresponding to
NYHA classes II and III
<35%† 48
Hoshida et al. 2013 [18] 313 70 74 1 Post-MI 47 39
Abbreviations: AECG ambulatory electrocardiogram, CHF chronic heart failure, LVEF left ventricular ejection fraction, MI myocardial infarction, NYHA New York Heart
Association, - not stated. *Ninety-two percent patients had LVEF greater than 35%. †Fifty-five percent patients had LVEF smaller than 35%.
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positive (HR: 2.29, 95% CI: 1.31–4.00).
We pooled data across studies to investigate the pre-
dictive ability of TWA (Tables 2 and 3). In our primary
analysis of the composite endpoint of SCD, cardiac mor-
tality, and severe arrhythmic events, the risk of patients
with positive TWA results was significantly increased
compared to negative results (HR: 5.94, 95% CI: 1.80 to
19.63) (Figure 2, Table 3). Subgroup summary estimates
showed that TWA-positive outcome was associated with
increased risk of SCD (HR: 7.49, 95% CI: 2.65 to 21.15)
and cardiac mortality (HR: 4.75, 95% CI: 0.42 to 53.55)
(Table 3). Four studies evaluating TWA measured using
the modified moving average (MMA) method, MMA-
TWA-positive outcome was significantly associated with
the composite endpoint (SCD, cardiac mortality, and
severe arrhythmic events, HR: 9.51, 95% CI: 4.99 to 18.11).
Discussion
We conducted the first meta-analysis of 24-hour AECG-
based TWA as a predictor of cardiac events in a wide var-
iety of patient populations, accumulating prospective data
on more than 1,500 subjects. Overall, we have found that
a positive TWA result predicted nearly six-fold risk of
composite endpoint (SCD, cardiac mortality, and severe
arrhythmic events) compared with a negative result.
As for the study that didn’t provide HR [23], 199
patients (mean age was 62 years, mean LVEF was 45%)
with AMI undergoing 24-hour Holter ECG-based TWATable 2 Test characteristics of AECG-based TWA
Study End Point HR (95% CI) P value
Sakaki et al. 2009 [19] Cardiac mortality* 17.1 (6.3–46.6) P <0.00
Sulimov et al. 2012 [20] SCD 5.01 (1.5–17.0) 0.005
Yu et al. 2012 [21] SCD 15.07 (2.88-78.68) 0.0031
Monasterio et al.
2012 [22]
Cardiac mortality 1.44 (0.97–2.13) 0.068
Hoshida et al. 2013 [18] Fatal arrhythmic events 5.8 (1.6–20.8) 0.0072
Abbreviations: AECG ambulatory electrocardiogram, HR hazard ratio, MMA modified
stated. *One patient who received ICD defibrillation therapy was included.assessment using the modified moving average (MMA)
method. The primary outcome was sudden death and
sustained ventricular arrhythmia treated with external
electric cardioversion during 6-month follow-up period.
TWA was positive in 8.5% patients (cut-off value was 46
μV). Survival analyses using Cox survival models revealed
that TWA was not significantly associated with the inci-
dence of the primary outcome (P = 0.15).
Studies with exercise-based and AECG-based TWA
have shown that an abnormal TWA test indicates an
increased risk for arrhythmic events or mortality [1-3,5].
Studies with the exercise-based TWA is more extensive
[1,2]. However, measurement of exercise-based TWA using
spectral method requires a specialized protocol and a target
heart rate range of 105 to 110 beats/min for >2 min [1,6].
As a result, spectral method has limited applicability in
patients with heart failure or undertake beta-blocking
agents. For studies with high ineligible rate (49% to 53%)
of spectral method-based TWA test results in decompen-
sated heart failure [7] and post-AMI [8] patients, the
incomplete TWA test was the most significant predictor
of mortality. Moreover, of the patients able to perform the
test, TWA did not predict mortality in both studies [7,8].
Alternative strategies would be required for the significant
proportion of ineligible patients.
Furthermore, spectral method has a relatively high
incidence (19% to 46%) of indeterminate test results
[1,7,9-11], rising debating on the interpretation of TWA
test results. The interpretation of indeterminate TWA inTWA Pos % TWA Neg % Cut-off value (μV) Lead Method
01 18 82 65 V1 or V5 MMA
41 59 53.5 - MMA
22 88 47 V2 or V5 MMA
24 76 3 - LLR
5 95 64 V1 or V5 MMA
moving average, Neg negative, Pos positive, SCD sudden cardiac death, - not
Table 3 Combined HR of AECG-based TWA related to fatal
cardiac events by endpoint and study method
Group No. of studies HR (95% CI)
Composite endpoint: SCD,
cardiac mortality, and severe
arrhythmic events
5 5.94 (1.80 to 19.63)
Endpoint: SCD 2 7.49 (2.65 to 21.15)
Sulimov et al.
Yu et al.
Endpoint: Cardiac mortality 2 4.75 (0.42 to 53.55)
Sakaki et al.
Monasterio et al.





Abbreviations: AECG ambulatory electrocardiogram, HR hazard ratio,
MMA modified moving average, SCD sudden cardiac death.
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history of that patient [1,9]. Recordings with respiration,
muscle, or other motion artifacts or electrode noise
provide no prognostic information [11]. Inconsistency re-
mains in current practice as to whether an indeterminate
TWA test should be considered abnormal [7-10,12-14].
Unlike the spectral method, AECG recording-based
TWA could be analyzed in 24-hour Holter recording
with daily activity, risk stratification is based on the peak
TWA value, which permits visual examination to verify
the presence and magnitude of TWA [15,25]. AECG
recording-based TWA does not require elevation of
heart rate to a target level, it affords an opportunity toFigure 2 Random-effects meta-analysis of prospective cohort studiesassess cardiac electrical instability in patients who cannot
exercise or taking beta-blocking agents [5,16,17]. Indeter-
minate results are infrequent (3% to 5%) as no target heart
rate is needed [2]. It remains important to use AECG-
based TWA to risk stratify the patients who are ineligible
for exercise-induced TWA test or have an indeterminate
result. Furthermore, AECG analysis allows patients to be
monitored for TWA during daily activity, incorporates
the influences of heightened sympathetic nerve activity,
disturbed nighttime breathing, and episodes of intense
physiological or mental stress, which cannot be repli-
cated during exercise stress tests.
Of the 5 included studies, 4 studies used the MMA
method [18-21], one study used the Laplacian likelihood
ratio (LLR) method [22]. Recently, Orini et al. performed
a simulation study in vivo in humans to compare the
accuracy of four commonly used methodologies, including
spectral, MMA and LLR methods, for T-wave alternans
mapping in electrograms [26]. They found that all meth-
odologies provided accurate electrogram-TWA estima-
tion/detection in ideal conditions, while LLR was the
most accurate and robust, providing better detection-
rates in noisy conditions.
MMA is the most used method employed for mea-
sures of AECG-based TWA in clinical studies [1,15].
There are two standard cut-points for MMA: 47 μV,
which indicates “abnormal” and 60 μV which indicates
“severely abnormal” test results [1]. Recently, it has become
possible to measure AECG-based TWA amplitude pre-
cisely [5]. It provides an opportunity for physicians to use
TWA magnitude in risk assessment.
Previously, a meta-analysis performed by Rizas et al.
shows that TWA using MMA method is powerful
predictor of mortality in post-MI patients (HR: 5.53,that examined AECG-based TWA and fatal cardiac events.
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included in their study, there are both case-control and
retrospective studies. Furthermore, TWA has been mea-
sured based on exercise or 24-hour AECG. There are
several strengths of our meta-analysis of TWA. First, all of
the studies analyzed the TWA based on the 24-hour
AECG. Second, we assessed the predictive value of AECG-
based TWA in a wide variety of patient populations,
including both ischemic and non-ischemic cardiomyopathy
with a wide range of LVEF. Finally, in contrast to many
earlier TWA studies, we used SCD, cardiac mortality, and
severe arrhythmic events, rather than all-cause mortality, as
the endpoint.
Study limitations
There are several limitations to this study. First, all data
were derived from prospective cohort studies of AECG-
based TWA. We did not identify any randomized studies
meeting our inclusion criteria. Second, the 5 included
studies varied in study design, patient characteristics and
duration of follow-up. Nevertheless, there was no statis-
tical evidence of heterogeneity. Third, the end points of
the individual studies used in the summary calculations
were slightly different (e.g., cardiac mortality vs. SCD vs.
fatal arrhythmic events) and may have introduced some
inconsistency when comparing across studies. Finally,
there were not sufficient data contained in the included
studies to determine the incremental prognostic value of
AECG-based TWA independent of other predictors of
arrhythmic events, such as heart rate variability, heart
rate turbulence, baroreflex sensitivity, or LVEF. Although
AECG-based TWA seems clinically useful in this meta-
analysis, the additional prognostic value of AECG-based
TWA when used with other predictors of risk stratifica-
tion is unclear.
Conclusions
We studied the use of AECG-based TWA as a predictor
of cardiac events in a meta-analysis of more than 1,500
subjects. We found that the positive TWA result pre-
dicted a nearly six-fold risk of a cardiac event compared
with the negative result. Given the challenge of risk
stratification for fatal cardiac events that faces today’s
cardiologist and the economic implications for today’s
healthcare system, our study helps understand the value
and the limitations of AECG-based TWA.
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